VALACYCLOVIR THERAPY OF SHINGLES IN IMMUNOCOMPETENT PATIENTS

万乃洛韦1.5克，每日2次，用于治疗18岁及以上免疫功能正常患者的局限性带状疱疹是安全有效的。这是一项开放标签的单中心试验，旨在确定万乃洛韦1.5克的疗效和安全性，BID用于治疗18岁及以上免疫功能正常的无并发症带状疱疹患者。50岁以下患者的研究总持续时间为4周。患者将接受疼痛、异常感觉、带状疱疹并发症、生活质量和资源使用情况的评估。安全性将通过监测临床化学和血液学以及报告不良反应(AEs)进行评估。慢性带状疱疹相关性疼痛明显更常见于50岁的患者。这些患者将被跟踪24周，因为大多数接受抗病毒治疗的患者将在24周前停止出现带状疱疹并发症。

Valacyclovir 1.5 gram BID is safe and effective for treatment of localized herpes zoster in immunocompetent patients 18 years of age and older. This is an open label single center trial to determine the efficacy and safety of valacyclovir 1.5 grams BID for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age and older. The total duration of the study in patients under 50 years of age is 4 weeks. Patients will be evaluated for pain, abnormal sensations, zoster complications, quality of life and resource use. Safety will be assessed by monitoring clinical chemistry and hematology and by reporting adverse experiences (AEs). Chronic zoster-associated pain is markedly more common in patients >50 years old. These patients will be followed for 24 weeks, as most patients on antiviral therapy will cease to experience complication of zoster by week 24.